Stock listing

OTC:BGMD BG Medicine Inc Stock

Follow BG Medicine Inc into a list and get an email when it puts out news.

Share price · OTC:BGMD

$0.0001 USD 0.0000 (0.0%)

Close on Nov 5, 2026

Past year 0.0% · daily closes, Nov 5, 2025 – Nov 5, 2026, adjusted for splits
Day range
$0.0001 – $0.0001 USDNov 5, 2026
Market cap
$1,137 USDAt the close on Nov 5, 2026 · price × 11.37M shares outstanding
52-week range
$0.0001 – $0.0001 USDLowest and highest trades, Nov 6, 2025 – Nov 5, 2026
Traded on an average day
$0 USDMedian day 0 shares · 64 days with no trades · last 3 months, Aug 5, 2026 – Nov 5, 2026
BG Medicine Inc logo

Daily closes

Last 3 months, Aug 5, 2026 – Nov 5, 2026 · OTC:BGMD · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00015,170
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.000112,675
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010

Splits

1 split · OTC:BGMD · every price before a split is adjusted for it

DayRatioWhat
1-for-4Consolidation
Ticker
OTC:BGMD
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
OTC
Currency
USD

Latest news

All BG Medicine Inc news

BG Medicine Inc on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
6 in all · newest Dec 23, 2015 · oldest 2015
Decks
1 deck · latest Feb 13, 2012

Valuation

price Nov 5, 2026

Enterprise value
No statements on 6ix yet
P/E
No statements on 6ix yet
EV/sales
No statements on 6ix yet
EV/EBITDA
No statements on 6ix yet
Price/book
No statements on 6ix yet
Gross margin
No statements on 6ix yet
Operating margin
No statements on 6ix yet
Net margin
No statements on 6ix yet
Debt to equity
No statements on 6ix yet
Beta vs S&P 500
0.00

Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
BG Medicine Inc · OTC:BGMDUS$1,137n/an/an/an/an/an/an/a0.00
Qlife Holding AB · OMXSTO:QLIFEUS$2.49MUS$2.88Mn/a34.1×n/a9.6×n/a3.1×n/a
Physiomics PLC · LSE:PYCUS$2.46MUS$1.91Mn/a1.6×n/a3.6×−74.1%0.0×n/a
20/20 BioLabs, Inc. · NASDAQ:AIDXUS$2.10M−US$1.01Mn/a−0.5×n/a3.4×−317.8%0.9×1.41
Bluejay Diagnostics, Inc. · NASDAQ:BJDXUS$1.90M−US$5.43Mn/an/an/a0.3×n/a0.0×1.71
Accustem Sciences Inc · OTC:ACUTUS$1.90MUS$1.88Mn/an/an/an/an/an/a0.19
InVitro International · OTC:IVROUS$1.87MUS$644,26029.6×0.8×14.0×1.1×8.2%0.0×0.17
Co-Diagnostics, Inc. · NASDAQ:CODXUS$1.36MUS$2.21Mn/a2.6×n/a0.1×n/a0.2×2.16
Prostatype Genomics AB · OMXSTO:PROGENUS$1.36MUS$1.32Mn/a13.3×n/a2.1×n/a0.0×n/a
Virax Biolabs Group Limited · NASDAQ:VRAXUS$446,402−US$5.66Mn/a−455×n/a0.1×n/a0.1×1.38
Oxurion NV · EURONEXT:OXURUS$254,615US$12.85Mn/a21.1×n/an/a−671.7%n/an/a
Median of the othersUS$1.88MUS$1.60M29.6×2.1×14.0×1.6×−195.9%0.0×1.40

Team and board

Officers

OfficerRole
Paul R. SohmerDirector, President and CEO
Charles H. AbdalianExecutive Vice President and CFO
Aram AdourianSenior Vice President and Chief Scientific Officer
Carol A. AdilettoVice President, Clinical and Regulatory Affairs
Howard RosenVice President, Sales and Marketing
Stacie RaderSenior Vice President, Executive Operations & Human Resources
Thomas B. MortensenVice President, Sales - Europe
Stéphane BancelExecutive Chairman of the Board

Board

DirectorRole
Stéphane BancelExecutive Chairman of the Board
Brian S. PosnerDirector
Harrison M. BainsDirector
Noubar AfeyanDirector
Paul R. SohmerDirector, President and CEO
Stelios PapadopoulosDirector
Timothy HarrisDirector

Events

QuarterResultsShare move
Quarter to Sep 30, 2024Nov 19, 20240.0%
Quarter to Jun 30, 2024Aug 19, 2024
Quarter to Mar 31, 2024May 16, 2024
Quarter to Dec 31, 2023Feb 28, 2024
Quarter to Sep 30, 2023Nov 14, 2023
Quarter to Jun 30, 2023Aug 14, 2023
Quarter to Mar 31, 2023May 11, 2023
Quarter to Dec 31, 2022Mar 1, 2023
Quarter to Sep 30, 2022Nov 15, 2022+50.0%
Quarter to Jun 30, 2022Aug 15, 2022
All 16 quarters
QuarterResultsShare move
Quarter to Mar 31, 2022May 12, 2022
Quarter to Dec 31, 2021Mar 2, 2022
Quarter to Sep 30, 2021Nov 16, 2021
Quarter to Jun 30, 2021Aug 16, 2021
Quarter to Mar 31, 2021May 13, 2021
Quarter to Dec 31, 2020Mar 3, 2021

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (February 2012)Investor deck35 slidesFeb 13, 2012

Open Decks

Financials

Annual, in USD

Income statement

LineFY2022FY2021FY2020FY2019FY2015FY2014FY2013FY2012FY2011FY2010
Revenue1.57M2.79M4.07M2.81M1.63M819.0K
Cost of revenue505.0K956.0K1.39M957.0K619.0K786.0K
Gross profit1.06M1.83M2.68M1.86M1.01M33.0K
Research and development1.77M2.39M3.73M7.58M8.00M6.54M
Selling, general and administrative3.62M4.51M7.13M7.55M10.5M
Operating income-4.63M-7.36M-14.4M-22.7M-17.5M-14.6M
Depreciation and amortization228.5K236.6K206.3K171.9K87.0K131.0K165.0K273.0K420.0K540.0K
EBITDA-4.54M-7.23M-14.2M-22.5M-17.1M-14.1M
Interest expense159.0K728.0K1.17M1.08M89.0K2.79M
Income before tax-5.30M-8.06M-15.8M-23.8M-17.5M-14.4M
Income tax159.0K597.0K1.00M810.0K-323.0K2.56M
Net income-5.30M-8.06M-15.8M-23.8M-17.6M-17.2M
Earnings per share, basic-0.55-0.99-2.33-4.70-3.99-23.10

Balance sheet

LineFY2022FY2021FY2020FY2019FY2015FY2014FY2013FY2012FY2011FY2010
Cash and equivalents1.52M4.12M7.75M12.8M23.9M2.42M
Short-term investments390.0K565.0K
Receivables181.0K174.0K319.0K395.0K115.0K786.0K
Inventory145.0K400.0K459.0K447.0K212.0K
Current assets1.95M4.85M8.84M14.6M25.3M3.62M
Property, plant and equipment11.0K117.0K192.0K197.0K301.0K604.0K
Total assets2.13M5.23M9.35M15.2M26.1M7.03M
Accounts payable558.0K695.0K965.0K1.11M487.0K1.38M
Current liabilities1.18M4.58M7.35M8.31M5.20M12.1M
Long-term debt2.96M6.61M
Total debt2.96M7.31M9.86M96.0K
Total liabilities4.11M4.67M10.4M14.9M5.22M84.4M
Shareholders' equity-1.98M557.0K-1.07M309.0K20.9M-77.4M
Shares outstanding9.61M9.61M9.61M9.61M9.61M8.18M6.80M5.05M4.41M742.9K

Cash flow

LineFY2015FY2014FY2013FY2012FY2011FY2010
Cash from operations-3.67M-8.17M-15.3M-21.3M-15.0M-11.4M
Capital spending00-132.0K-85.0K-93.0K-77.0K
Free cash flow-3.67M-8.17M-15.4M-21.4M-15.1M-11.5M
Cash from investing13.0K13.0K-32.0K-85.0K-93.0K1.98M
Cash from financing1.06M4.54M10.3M10.3M36.5M3.52M
Dividends paid-2.50M
Share buybacks-456.0K9.02M13.1M586.0K36.6M
Change in cash-2.60M-3.63M-5.04M-11.1M21.4M-5.92M

Open Financials

Cap table

Built by 6ix from BG Medicine Inc’s releases

Common shares
11,374,360
Fully diluted
11,374,360

Fully diluted

LineShares
Common shares11,374,360

Share count over time

CountShares
Nov 22, 202611,374,360

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Noubar Afeyan
Other companies: Generate Biomedicines, Inc. (Chair of the Board · Since at least Feb 26, 2026); Foghorn Therapeutics Inc. (Director · Since at least Jan 13, 2026); Moderna, Inc. (Director · Since at least Dec 7, 2018); Omega Therapeutics Inc (Director · Jul 29, 2021 – Jun 7, 2023 · Past); Kaleido Biosciences, Inc. (Director · Feb 27, 2019 – Mar 4, 2019 · Past); Rubius Therapeutics Inc (Director · Jul 17, 2018 – May 12, 2022 · Past); Evelo Biosciences, Inc. (Director · May 8, 2018 – Jun 12, 2019 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 21, 2016 · Past); Seres Therapeutics, Inc. (Director · Jun 25, 2015 – Jun 18, 2019 · Past); Eleven Biotherapeutics Inc (Director · Feb 5, 2014 – Mar 20, 2014 · Past); BIND Therapeutics Inc (Director · Sep 19, 2013 – Sep 25, 2013 · Past); Color Kinetics Inc (Director · Jan 3, 2006 – Aug 24, 2007 · Past); Agenus Inc. (Director · Jan 13, 2005 – Jun 7, 2007 · Past)
Director · Since at least Feb 3, 2011
Michael Rogers
Other companies: Akebia Therapeutics, Inc. (Director · Since at least Dec 12, 2018); Aravive Inc (Director · Sep 15, 2020 – Sep 23, 2022 · Past); Whitehawk Therapeutics, Inc. (See Remarks · Nov 15, 2017 – May 14, 2019 · Past); Keryx Biopharmaceuticals Inc (Director · Mar 31, 2016 – Dec 12, 2018 · Past); Acorda Therapeutics Inc (Chief Financial Officer · Oct 7, 2013 – May 11, 2016 · Past); Fortress Biotech, Inc. (Director · Sep 13, 2011 – Feb 7, 2013 · Past); EyePoint, Inc. (Director · Jul 13, 2007 – Jun 25, 2019 · Past); Indevus Pharmaceuticals Inc (Executive Vice President · Feb 17, 2006 – Feb 23, 2009 · Past)
EVP, CFO and Treasurer · Feb 3, 2010 – Feb 22, 2012 · Past
Brian S. Posner
Other companies: Dyne Therapeutics, Inc. (Board Member · Since at least Oct 1, 2025); Arch Capital Group Ltd. (Director · Since at least Nov 4, 2010); Bioverativ Inc (Director · Jan 10, 2017 – Mar 8, 2018 · Past); Anadys Pharmaceuticals Inc (Director · Aug 22, 2011 – Aug 22, 2011 · Past); Biogen Inc. (Director · Jul 23, 2008 – Dec 31, 2022 · Past); LMP Capital and Income Fund Inc (Officer of the Adviser · Oct 11, 2006 – Oct 11, 2006 · Past)
Director · Since at least Feb 13, 2012
Stelios Papadopoulos
Other companies: Ovid Therapeutics Inc. (Director, Member of the Audit and Compensation Committees · Since at least Mar 1, 2025); Regulus Therapeutics Inc (Director · Since at least Oct 4, 2012); Exelixis, Inc. (Chair of the Board, Exelixis, Inc. · Since at least May 24, 2012); Eucrates Biomedical Acquisition Corp. (Director · Oct 23, 2020 – Nov 24, 2020 · Past); Biogen Inc. (Director · Jun 8, 2012 – Jun 15, 2022 · Past)
Director · Since at least Nov 9, 2011
Stéphane Bancel
Other companies: Generate Biomedicines, Inc. (Director · Since at least Feb 26, 2026); Moderna, Inc. (Chief Executive Officer, Moderna · Since at least Dec 7, 2018); Syros Pharmaceuticals, Inc. (Director · Jun 29, 2016 – Sep 15, 2016 · Past); Targanta Therapeutics Corp (Director · Aug 25, 2008 – Aug 25, 2008 · Past)
Executive Chairman of the Board · Since at least Feb 3, 2011
Harry W Wilcox
Other companies: T2 Biosystems, Inc. (Director · Aug 6, 2014 – Jun 17, 2016 · Past); EXACT Sciences Corporation (Senior Vice President and CFO · Feb 16, 2006 – Feb 16, 2006 · Past)
Director · May 12, 2015 – Nov 18, 2015 · Past
Timothy Harris
Other companies: Bioverativ Inc (EVP, R & D · Apr 10, 2017 – Mar 8, 2018 · Past); CapForce Inc. (Director · May 4, 2015 – Jun 13, 2018 · Past)
Director · Since at least Feb 3, 2011
Charles H Abdalian Jr
Other companies: Coley Pharmaceutical Group Inc (SVP, Finance and CFO · Feb 16, 2007 – Jan 4, 2008 · Past)
EVP & Chief Financial Officer · Oct 18, 2012 – Dec 10, 2012 · Past
Harrison M Bains Jr
Other companies: Tvardi Therapeutics, Inc. (Director · Jul 16, 2014 – Jun 1, 2023 · Past)
Director · Jun 12, 2013 – Jun 3, 2014 · Past
Jeffrey R Luber
Other companies: EXACT Sciences Corporation (President and CEO, Director · Feb 16, 2006 – Mar 31, 2009 · Past)
Director · Feb 4, 2016 – Feb 4, 2016 · Past
All 24 people
PersonSeat
Anastasia RaderSVP, Executive Operations & HR · Apr 26, 2013 – Feb 4, 2014 · Past
Aram AdourianSenior Vice President and Chief Scientific Officer · Since at least Feb 3, 2011
Carol A. AdilettoVice President, Clinical and Regulatory Affairs · Since at least Nov 4, 2026
Charles H. AbdalianExecutive Vice President and CFO · Since at least Nov 5, 2026
Eric BouvierPresident, CEO, Director · Jan 9, 2012 – May 23, 2012 · Past
Harrison M. BainsDirector · Since at least Nov 5, 2026
Howard RosenVice President, Sales and Marketing · Since at least Nov 4, 2026
Neal GordonSVP, Biomarker Discovery · Feb 3, 2011 – Feb 22, 2012 · Past
Paul R. SohmerDirector, President and CEO · Since at least May 8, 2013
Pieter MuntendamEVP, Chief Medical Officer · Feb 3, 2011 – Jun 7, 2012 · Past
Pieter van der MeerDirector · Feb 3, 2011 – Feb 9, 2011 · Past
Stacie RaderSenior Vice President, Executive Operations & Human Resources · Since at least Nov 4, 2026
Thomas B. MortensenVice President, Sales - Europe · Since at least Nov 4, 2026
William DenselGeneral Manager, CardioSCORE · Aug 8, 2012 – Aug 8, 2012 · Past

Open People

Log in to ask 6ix AI your own questions about BG Medicine Inc.